GLP-1 peptides for weight loss
Compounded GLP-1 peptides (semaglutide and tirzepatide) are the most-studied prescription weight-loss medications available today. Rx Peps Direct (RxPepsDirect.com) prescribes both molecules in two carrier formulations each: a B-12 variant (the default) and a glycine variant for patients with documented B-12 sensitivity. The active ingredient is identical to the branded products (Ozempic, Wegovy, Mounjaro, Zepbound). A licensed U.S. 503A compounding pharmacy compounds and dispenses every prescription.
- Tirzepatide produced 20.2 percent mean weight loss in SURMOUNT-5; semaglutide produced 13.7 percent at equivalent doses.
- Both molecules ship pre-reconstituted from a licensed U.S. 503A compounding pharmacy. No bacteriostatic water required.
- Glycine variants are reserved for B-12 sensitivity, methylation issues, or histamine reactions.
- Flat $39 medical review covers the whole protocol; medication is billed separately at pharmacy wholesale.
Semaglutide/B12
From $9.60/1.2mgThe gold standard GLP-1 for weight management, paired with B12 for energy support.
Semaglutide/B6 + Glycine
From $175/10mgGlycine-buffered semaglutide for patients who don't tolerate the B12 cofactor.
Glycine carrier: reserved for patients with B-12 sensitivity, methylation issues, or histamine reactions. Higher carrier cost reflects formulation complexity, not the peptide itself.
Semaglutide Microdose
$9.60/1.2mgA gentle twice-weekly microdose of compounded semaglutide with vitamin B12, for a slower, lower-side-effect approach to GLP-1 support.
Tirzepatide/B12
From $36/12mgDual GIP/GLP-1 receptor agonist for enhanced metabolic support with B12.
Tirzepatide/B6 + Glycine
From $180/60mgGlycine-buffered tirzepatide for patients who don't tolerate the B12 cofactor.
Glycine carrier: reserved for patients with B-12 sensitivity, methylation issues, or histamine reactions. Higher carrier cost reflects formulation complexity, not the peptide itself.
Tirzepatide Microdose
$36/12mgA gentle twice-weekly microdose of compounded tirzepatide with vitamin B12, for a slower, lower-side-effect approach to dual-pathway GLP-1 support.
Ondansetron 4mg ODT
$1.25/tabletAnti-nausea adjunct for GLP-1 patients. Generic Zofran orally disintegrating tablets.
AOD-9604
$801.2mg/mL, 5mL vial (6mg total)
A modified fragment of human growth hormone that targets fat metabolism without growth effects.
AOD-9604 Troche
$2.50/trocheSublingual AOD-9604 troche. The growth hormone fragment that targets fat metabolism, in a no-needle daily form.
Lean Stack (SS-31/MOTs-C/Tesamorelin)
$1255mL vial of 3 peptides
Three-peptide metabolic blend in one vial: tesamorelin for the growth hormone pathway, MOTs-C for metabolic signaling, and SS-31 for mitochondrial function.
5-Amino-1MQ
$805mg/mL, 5mL vial (25mg total)
An NNMT inhibitor that activates cellular energy pathways to boost metabolism.
Tesofensine
$2.25/capA triple monoamine reuptake inhibitor that suppresses appetite through central nervous system pathways.
Lipo-B (Cyanocobalamin/MIC)
From $30/10mlA lipotropic injection combining cyanocobalamin (B12) with methionine, inositol, and choline for fat metabolism.
Lipo-C (Cyanocobalamin/MIC/L-Carnitine)
From $35/10mlEnhanced lipotropic injection adding L-carnitine to cyanocobalamin and MIC for improved energy and fat transport.
Comparing semaglutide and tirzepatide formulations
Side-by-side at-a-glance comparison of every weight-loss peptide Rx Peps Direct prescribes. Pricing is pharmacy wholesale passed through with no markup.
| Semaglutide/B12 | Semaglutide/Glycine | Tirzepatide/B12 | Tirzepatide/Glycine | AOD-9604 | |
|---|---|---|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist | Dual GLP-1 / GIP | Dual GLP-1 / GIP | Lipolysis fragment |
| Carrier | B-12 | Glycine + B6 | B-12 | Glycine + B6 | None |
| Mean trial loss | ≈14.9% (STEP-1, 68 wk) | ≈14.9% (STEP-1, 68 wk) | 15-22% (SURMOUNT-1, 72 wk) | 15-22% (SURMOUNT-1, 72 wk) | Modest (mixed data) |
| Best for | Standard GLP-1 candidate | B-12 sensitive patient | Strongest weight loss | B-12 sensitive + maximum loss | Adjunct to GLP-1 or alone |
| Starting price | From $9.60 / 1.2 mg | From $175 / 10 mg | From $36 / 12 mg | From $180 / 60 mg | $80 / 6 mg |
| Medical review | $39 | $39 | $39 | $39 | $39 |
What to expect on compounded GLP-1 therapy
Most patients start at 25 units (1.5 mg) of tirzepatide twice weekly or 25 units (0.15 mg) of semaglutide twice weekly. Titration is typically every 4 weeks if tolerated. Nausea is the most common side effect during titration and is mitigated by slow up-titration plus PRN ondansetron when needed. Hair shedding is reported in 3 to 5 percent of patients and is generally tied to rapid weight loss rather than the medication itself. Adequate protein intake (1 g per kg body weight or higher) reduces both lean-mass loss and shedding risk.
Important Safety Information
- •Personal/family history of medullary thyroid carcinoma (MTC)
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- •Active pancreatitis
- •Severe gastroparesis
- •Pregnancy or breastfeeding
- •Current use of insulin (flag for medical review)
- •Active eating disorder history
Frequently asked questions about weight loss & metabolic peptides
- Tirzepatide vs semaglutide: which loses more weight?
- Head-to-head trial data (SURMOUNT-5, 2025) showed tirzepatide produced 20.2 percent mean weight loss versus semaglutide's 13.7 percent at equivalent therapeutic doses over 72 weeks. Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide is GLP-1-only. Tirzepatide also tends to produce stronger nausea during titration; patients with severe GI history sometimes prefer semaglutide.
- How fast does compounded tirzepatide work for weight loss?
- Most patients notice appetite suppression within 1 to 2 weeks of starting tirzepatide. Measurable weight loss appears around weeks 4 to 8 as the dose titrates up. Pivotal trial data shows 15 to 22 percent mean body weight loss over 72 weeks at therapeutic doses. Rx Peps Direct prescribes a 1.5 mg twice-weekly starter protocol (3 mg per week total) to smooth the plasma peak and reduce nausea during titration.
- Is compounded tirzepatide as effective as Mounjaro or Zepbound?
- The active ingredient is identical: tirzepatide. The dose-response and weight-loss mechanism are the same because the molecule is the same. Compounded tirzepatide uses a different dosing schedule (1.5 mg twice weekly versus 2.5 mg once weekly for branded) to smooth the Cmax peak that drives nausea. A licensed U.S. 503A compounding pharmacy tests every batch for sterility (ScanRDI or Celsis) and bacterial endotoxin (USP <85>); the Certificate of Analysis is published on every product page.
- What is the cheapest compounded GLP-1 from Rx Peps Direct?
- Semaglutide/B12 is the cheapest entry point at $9.60 for the 1.2 mg starter vial, plus the flat $39 medical review. Tirzepatide/B12 starts at $36 for the 12 mg starter vial. The Glycine variants start higher because their smallest vials hold more: Semaglutide/Glycine starts at $175 for 10 mg, and Tirzepatide/Glycine at $180 for 60 mg, the same $3.00 per mg as Tirzepatide/B12. They are reserved for patients with B-12 sensitivity rather than as a default.
- Why does Rx Peps Direct offer two semaglutide formulations (B12 and Glycine)?
- The B-12 variant is the default formulation and supports energy metabolism during caloric restriction. Some patients have documented B-12 sensitivity, MTHFR methylation variants, or histamine reactions to cyanocobalamin. The Glycine variant uses glycine plus vitamin B6 as the carrier instead, with no B-12. The active ingredient (semaglutide) and weight-loss effect are identical across both formulations.
Protocol guides for weight loss & metabolic
Clinical guides covering the molecules in this category. Mechanism, dosing, evidence, and what the research does not yet support.
GLP-1 protocol guide
Microdose GLP-1: dosing math, evidence, and how to start safely in 2026
Microdosing semaglutide or tirzepatide means running them below the FDA-approved starter dose. The vial-duration math, the published evidence, and how to start with a provider.
Triple monoamine reuptake inhibitor (weight loss)
Tesofensine protocol guide: triple monoamine mechanism, Phase IIb data, and the cardiovascular signal
Not a peptide despite frequent miscategorization. 9.2 percent Phase IIb weight loss. Real cardiovascular signal. Monitoring is not optional.
NNMT inhibitor (metabolic weight-loss)
5-Amino-1MQ protocol guide: the NNMT inhibitor mechanism, the mouse data, and the missing human trial
A small-molecule NNMT inhibitor that raises cellular NAD+ to push fat cells toward burning energy. All weight evidence is preclinical mouse and cell-culture work. Honest that no human trial exists.
Growth hormone fragment fat-loss protocol
AOD-9604 (GH fragment 176-191) protocol guide: the lipolysis mechanism, the failed obesity trial, and the honest fat-loss picture
A growth hormone fragment built to burn fat without raising IGF-1. The rodent data is real, but the pivotal 534-subject obesity trial did not beat placebo and development stopped in 2007. Honest about the gap.
Lipotropic injection protocol
Lipotropic injections (Lipo-B / Lipo-C) protocol guide: what MIC, B12, and L-carnitine actually do, and the honest weight-loss evidence
MIC (methionine, inositol, choline) plus B12 or L-carnitine. The standalone fat-loss evidence is weak. These are adjuncts to diet and GLP-1 therapy, not primary weight-loss drugs.